ECSP034904A - Derivados de índole naftil sustituido como inhibidores del activador plasminogen del inhibidor tipo-1 (pai-1) - Google Patents
Derivados de índole naftil sustituido como inhibidores del activador plasminogen del inhibidor tipo-1 (pai-1)Info
- Publication number
- ECSP034904A ECSP034904A EC2003004904A ECSP034904A ECSP034904A EC SP034904 A ECSP034904 A EC SP034904A EC 2003004904 A EC2003004904 A EC 2003004904A EC SP034904 A ECSP034904 A EC SP034904A EC SP034904 A ECSP034904 A EC SP034904A
- Authority
- EC
- Ecuador
- Prior art keywords
- optionally substituted
- alkyl
- alkanoyl
- pai
- naftile
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
La presente invención provee PAI-1 inhibiendo compuestos de la Fórmula (I): donde: R1, R2, R3 y R4 son cada H, alquil, alcanoil, halo, OH, aril opcionalmente sustituido con R8, perfluoroalquil, alcoxi, amino, alquilamino, dialquilamino, perfluoroalcoxi; R5 es H, alquil perfluoroalquil, aril opcionalmente sustituido con R8, alcanoil, aroil opcionalmente sustituido con R8, R6 es H, alquil, alquilaril, bencilo opcionalmente sustituido con R8, alcanoil, aroil opcionalmente sustituido con R8, R7 es H, alquil, alquilaril, aril opcionalmente sustituido con R8, n es 0-6 es COOH, o un ácido imitante tales como tetraazole, SO3H, PO3H2, ácido tetrónico, etc., R8 es H, alquil, cicloalquil, alcanoil, halo, OH, perfluoroalquil, alcoxi, amino, alquilamino, dialquilamino, perfluoroalcoxi; o una sal aceptable farmacéuticamente del mismo; así como también composiciones farmacéuticas y métodos de tratamiento usando eso compuestos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29965101P | 2001-06-20 | 2001-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP034904A true ECSP034904A (es) | 2004-01-28 |
Family
ID=23155676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2003004904A ECSP034904A (es) | 2001-06-20 | 2003-12-17 | Derivados de índole naftil sustituido como inhibidores del activador plasminogen del inhibidor tipo-1 (pai-1) |
Country Status (25)
Country | Link |
---|---|
US (4) | US6800654B2 (es) |
EP (1) | EP1397356B1 (es) |
JP (1) | JP4520144B2 (es) |
KR (1) | KR20040007744A (es) |
CN (1) | CN1280288C (es) |
AR (1) | AR036101A1 (es) |
AT (1) | ATE431346T1 (es) |
AU (1) | AU2002316533B2 (es) |
BR (1) | BR0210504A (es) |
CA (1) | CA2448798C (es) |
CO (1) | CO5540286A2 (es) |
DE (1) | DE60232328D1 (es) |
EA (1) | EA009696B1 (es) |
EC (1) | ECSP034904A (es) |
ES (1) | ES2325733T3 (es) |
HU (1) | HUP0400233A3 (es) |
IL (1) | IL159449A0 (es) |
MX (1) | MXPA03011522A (es) |
NO (2) | NO326316B1 (es) |
NZ (1) | NZ530312A (es) |
PL (1) | PL367525A1 (es) |
TW (1) | TWI224101B (es) |
UA (1) | UA78708C2 (es) |
WO (1) | WO2003000684A1 (es) |
ZA (1) | ZA200400380B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4399253B2 (ja) * | 2001-06-20 | 2010-01-13 | ワイス | プラスミノゲンアクチベーターインヒビター−1(pai−1)のインヒビターとしての、置換されたインドール酸誘導体 |
TWI224101B (en) * | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
US7291639B2 (en) * | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
JP2006510672A (ja) * | 2002-12-10 | 2006-03-30 | ワイス | プラスミノーゲン活性化因子の阻害因子−1(pai−1)の阻害剤としての置換インドールオキソ−アセチルアミノ酢酸誘導体 |
UA80453C2 (en) * | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
DE60324183D1 (en) * | 2002-12-10 | 2008-11-27 | Wyeth Corp | Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) |
DE60306547T2 (de) * | 2002-12-10 | 2007-06-28 | Wyeth | Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen-aktivator |
DE60306548T2 (de) | 2002-12-10 | 2007-06-21 | Wyeth | Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren |
JP4390460B2 (ja) * | 2003-02-21 | 2009-12-24 | 株式会社静岡カフェイン工業所 | オキサゾール誘導体 |
US7342039B2 (en) * | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
US7582773B2 (en) * | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
US7420083B2 (en) * | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
US7351726B2 (en) * | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
US7163954B2 (en) * | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
US7442805B2 (en) * | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
US7265148B2 (en) * | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
US7534894B2 (en) * | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
US7332521B2 (en) * | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
US7268159B2 (en) * | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
US7446201B2 (en) * | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
US7411083B2 (en) * | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
US7141592B2 (en) * | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
US7115815B2 (en) * | 2003-10-31 | 2006-10-03 | Adc Telecommunications, Inc. | Cable utilizing varying lay length mechanisms to minimize alien crosstalk |
WO2006023866A2 (en) | 2004-08-23 | 2006-03-02 | Wyeth | Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1 |
CN101039936A (zh) * | 2004-08-23 | 2007-09-19 | 惠氏公司 | 作为i-型纤溶酶原激活剂抑制剂(pai-1)调节剂用于治疗血栓形成和心血管疾病的唑基-萘基酸 |
CN101044136A (zh) * | 2004-08-23 | 2007-09-26 | 惠氏公司 | 作为pai-1抑制剂的吡咯基-萘基酸 |
CA2595376A1 (en) * | 2005-01-27 | 2006-08-03 | Wyeth | Processes and compounds for the preparation of substituted naphthylindole derivatives |
CN101263115A (zh) * | 2005-08-17 | 2008-09-10 | 惠氏公司 | 经取代吲哚和其用途 |
MX2008011015A (es) * | 2006-02-27 | 2008-11-14 | Wyeth Corp | Inhibidores de pai-1 para tratamiento de afecciones musculares. |
JP5207972B2 (ja) | 2006-10-12 | 2013-06-12 | 株式会社医薬分子設計研究所 | カルボン酸誘導体 |
WO2008044731A1 (fr) | 2006-10-12 | 2008-04-17 | Institute Of Medicinal Molecular Design. Inc. | Dérivé d'acide n-phényloxamidique |
US9120744B2 (en) | 2007-04-16 | 2015-09-01 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism |
WO2008131047A2 (en) | 2007-04-16 | 2008-10-30 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism |
WO2009001949A1 (ja) | 2007-06-27 | 2008-12-31 | Kowa Company, Ltd. | ピラゾロン誘導体 |
CA2703494A1 (en) | 2007-10-23 | 2009-04-30 | Institute Of Medicinal Molecular Design, Inc. | Inhibitor of pai-1 production |
US8633245B2 (en) * | 2008-04-11 | 2014-01-21 | Institute Of Medicinal Molecular Design, Inc. | PAI-1 inhibitor |
EP2272817A4 (en) | 2008-04-11 | 2011-12-14 | Inst Med Molecular Design Inc | INHIBITOR OF PAI-1 |
CA2888996A1 (en) | 2012-10-31 | 2014-05-08 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof |
CN106890324A (zh) * | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病肾病的方法 |
CA3008686C (en) | 2015-12-18 | 2023-03-14 | Talengen International Limited | Method for preventing and treating diabetic nephropathy |
TWI644682B (zh) | 2016-12-15 | 2018-12-21 | 深圳瑞健生命科學硏究院有限公司 | 一種纖溶酶原在製備促進胰島細胞損傷修復的藥物上的用途 |
CN110869346B (zh) | 2017-07-27 | 2024-03-29 | 密歇根大学董事会 | 纤维蛋白溶酶原活化物抑制因子-1(pai-1)抑制剂和使用方法 |
CN114057623B (zh) * | 2021-12-07 | 2023-07-21 | 湖南第一师范学院 | 一种n-萘基吲哚衍生物及其合成方法 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3026325A (en) * | 1959-01-26 | 1962-03-20 | Upjohn Co | 5-hydroxy-alpha-alkyltryptophans |
US3476770A (en) * | 1967-04-14 | 1969-11-04 | Parke Davis & Co | 2-methyl-7-phenylindole-3-acetic acid compounds |
GB1321433A (en) | 1968-01-11 | 1973-06-27 | Roussel Uclaf | 1,2,3,6-tetrasubstituted indoles |
US3557142A (en) * | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
FR2244499A1 (en) | 1973-06-07 | 1975-04-18 | Delalande Sa | Indol-3-ylformaldoxime carbamates - for treating anxiety epilepsy, cardiac arrhythmias, asthma, intestinal spasm, peptic ulcer, cardiac insufficiency |
US4519909A (en) * | 1977-07-11 | 1985-05-28 | Akzona Incorporated | Microporous products |
DE3147276A1 (de) * | 1981-11-28 | 1983-06-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung von indolderivaten, deren verwendung als wertvolle zwischenprodukte und neue 4-hydroxyindole |
FR2525474A1 (fr) * | 1982-04-26 | 1983-10-28 | Roussel Uclaf | Nouvelle forme pharmaceutique orale de clometacine |
DE3531658A1 (de) * | 1985-09-05 | 1987-03-12 | Boehringer Mannheim Gmbh | Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel |
US4859538A (en) * | 1986-11-20 | 1989-08-22 | Ribi Hans O | Novel lipid-protein compositions and articles and methods for their preparation |
US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
IL95584A (en) | 1989-09-07 | 1995-03-15 | Abbott Lab | Indole-, benzoporene- and benzothiophene compounds including lipoxygenase-inhibiting compounds and pharmaceutical compounds containing them |
US5420289A (en) * | 1989-10-27 | 1995-05-30 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
DE4035961A1 (de) * | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US5151435A (en) | 1991-04-08 | 1992-09-29 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating an indole or dihydroindole |
IL101785A0 (en) | 1991-05-10 | 1992-12-30 | Fujisawa Pharmaceutical Co | Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
GB9123396D0 (en) | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
US5502187A (en) * | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
DE4242675A1 (de) | 1992-12-17 | 1994-06-23 | Basf Ag | Neue Hydroxyiminoalkylindolcarbonsäure-Derivate, ihre Herstellung und Verwendung |
ZA939516B (en) | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
IL109568A0 (en) | 1993-05-19 | 1994-08-26 | Fujisawa Pharmaceutical Co | Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
CA2134192A1 (en) | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
DE4338770A1 (de) | 1993-11-12 | 1995-05-18 | Matthias Dr Lehr | Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶ |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5482960A (en) * | 1994-11-14 | 1996-01-09 | Warner-Lambert Company | Nonpeptide endothelin antagonists |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
IL117208A0 (en) | 1995-02-23 | 1996-06-18 | Nissan Chemical Ind Ltd | Indole type thiazolidines |
JPH11503445A (ja) | 1995-04-10 | 1999-03-26 | 藤沢薬品工業株式会社 | cGMP−PDE阻害剤としてのインドール誘導体 |
US5728724A (en) | 1995-08-17 | 1998-03-17 | Eli Lilly And Company | Benzothiophene compounds |
WO1997009308A1 (en) | 1995-09-01 | 1997-03-13 | Eli Lilly And Company | Indolyl neuropeptide y receptor antagonists |
DE19543639A1 (de) | 1995-11-23 | 1997-05-28 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
GB9609641D0 (en) | 1996-05-09 | 1996-07-10 | Pfizer Ltd | Compounds useful in therapy |
CA2258728C (en) * | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
CA2207141A1 (en) * | 1996-07-15 | 1998-01-15 | David Thompson Berg | Benzothiophene compounds, and uses and formulations thereof |
CA2207083A1 (en) | 1996-07-15 | 1998-01-15 | Brian William Grinnell | Benzothiophene compounds, and uses and formulations thereof |
US5859044A (en) * | 1996-07-31 | 1999-01-12 | Pfizer Inc. | β-adrenergic agonists |
WO1998008818A1 (en) | 1996-08-26 | 1998-03-05 | Genetics Institute, Inc. | Inhibitors of phospholipase enzymes |
DE19753522A1 (de) | 1997-12-03 | 1999-06-10 | Boehringer Ingelheim Pharma | Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel |
PL343007A1 (en) | 1998-02-25 | 2001-07-30 | Genetics Inst | Inhibitors of phospholipase enzymes |
ID27280A (id) | 1998-02-25 | 2001-03-22 | Genetics Inst | Inhibitor-inhibitor dari enzim-enzim fosfolipase |
IL137540A0 (en) | 1998-02-25 | 2001-07-24 | Genetics Inst | Inhibitors of phospholipase a2 |
SE9800836D0 (sv) | 1998-03-13 | 1998-03-13 | Astra Ab | New Compounds |
ES2224632T3 (es) | 1998-03-31 | 2005-03-01 | The Institutes For Pharmaceutical Discovery, Inc. | Acidos indolalcanoicos sustituidos. |
FR2777886B1 (fr) | 1998-04-27 | 2002-05-31 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6166069A (en) * | 1998-05-12 | 2000-12-26 | American Home Products Corporation | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
AU756337B2 (en) | 1998-05-12 | 2003-01-09 | Wyeth | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia |
US6251936B1 (en) * | 1998-05-12 | 2001-06-26 | American Home Products Corporation | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia |
US6110963A (en) * | 1998-05-12 | 2000-08-29 | American Home Products Corporation | Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
US6232322B1 (en) * | 1998-05-12 | 2001-05-15 | American Home Products Corporation | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
AU3791799A (en) | 1998-05-12 | 1999-11-29 | American Home Products Corporation | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
WO2000031045A1 (fr) * | 1998-11-20 | 2000-06-02 | Torii Pharmaceutical Co., Ltd. | Derives de naphtalene |
TNSN99224A1 (fr) | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
CA2353151A1 (en) * | 1998-12-16 | 2000-06-22 | Boehringer Ingelheim Pharma Kg | Substituted aryl and heteroaryl derivatives, the preparation thereof and their use as medicaments |
GB9827882D0 (en) | 1998-12-17 | 1999-02-10 | Smithkline Beecham Plc | Novel compounds |
EP1156045A4 (en) | 1999-01-28 | 2002-04-17 | Nippon Shinyaku Co Ltd | AMID DERIVATIVES AND DRUG COMPOSITIONS |
GB9902459D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
DE60035682T2 (de) | 1999-04-28 | 2008-04-30 | Sanofi-Aventis Deutschland Gmbh | Di-aryl-säurederivate als ppar rezeptor liganden |
WO2000064876A1 (en) | 1999-04-28 | 2000-11-02 | Aventis Pharma Deutschland Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
GB9919411D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
GB9919413D0 (en) * | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
FR2799756B1 (fr) * | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE19963178A1 (de) * | 1999-12-27 | 2001-07-05 | Gruenenthal Gmbh | Substituierte Indol-Mannichbasen |
DE10031281A1 (de) * | 2000-06-27 | 2002-01-10 | Creavis Tech & Innovation Gmbh | Polyelektrolytbeschichteter, stoffdurchlässiger Verbundwerkstoff, Verfahren zu dessen Herstellung und die Verwendung des Verbundwerkstoffes |
CA2427499A1 (en) | 2000-10-10 | 2002-04-18 | Smithkline Beecham Corporation | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents |
EP1377549A1 (en) | 2001-03-12 | 2004-01-07 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
US6808908B2 (en) * | 2001-05-30 | 2004-10-26 | Porex Technologies Corporation | Functionalized porous substrate for binding chemical and biological moieties |
FR2825706B1 (fr) * | 2001-06-06 | 2003-12-12 | Pf Medicament | Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase |
TWI224101B (en) * | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
JP4399253B2 (ja) * | 2001-06-20 | 2010-01-13 | ワイス | プラスミノゲンアクチベーターインヒビター−1(pai−1)のインヒビターとしての、置換されたインドール酸誘導体 |
TWI240723B (en) * | 2001-06-20 | 2005-10-01 | Wyeth Corp | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
US7291639B2 (en) * | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
US7456025B2 (en) * | 2001-08-28 | 2008-11-25 | Porex Corporation | Sintered polymer membrane for analyte detection device |
KR100810468B1 (ko) | 2001-10-10 | 2008-03-07 | 씨제이제일제당 (주) | 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1h-인돌 유도체 |
EP1480951B1 (en) | 2002-02-12 | 2008-05-07 | Wisconsin Alumni Research Foundation | Synthesis of indole thiazole compounds as ligands for the ah receptor |
DE60306548T2 (de) * | 2002-12-10 | 2007-06-21 | Wyeth | Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren |
DE60324183D1 (en) * | 2002-12-10 | 2008-11-27 | Wyeth Corp | Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) |
JP2006510672A (ja) * | 2002-12-10 | 2006-03-30 | ワイス | プラスミノーゲン活性化因子の阻害因子−1(pai−1)の阻害剤としての置換インドールオキソ−アセチルアミノ酢酸誘導体 |
UA80453C2 (en) * | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
DE60306547T2 (de) * | 2002-12-10 | 2007-06-28 | Wyeth | Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen-aktivator |
US7163954B2 (en) * | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
US7268159B2 (en) * | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
US7582773B2 (en) * | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
US7332521B2 (en) * | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
US7141592B2 (en) * | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
US7446201B2 (en) * | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
US20050215626A1 (en) * | 2003-09-25 | 2005-09-29 | Wyeth | Substituted benzofuran oximes |
US7351726B2 (en) * | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
US7342039B2 (en) * | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
US7265148B2 (en) * | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
US7442805B2 (en) * | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
US7420083B2 (en) * | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
-
2002
- 2002-06-10 TW TW091112530A patent/TWI224101B/zh not_active IP Right Cessation
- 2002-06-13 US US10/171,041 patent/US6800654B2/en not_active Expired - Fee Related
- 2002-06-18 KR KR10-2003-7016636A patent/KR20040007744A/ko active IP Right Grant
- 2002-06-18 WO PCT/US2002/021113 patent/WO2003000684A1/en active IP Right Grant
- 2002-06-18 ES ES02746846T patent/ES2325733T3/es not_active Expired - Lifetime
- 2002-06-18 BR BR0210504-7A patent/BR0210504A/pt not_active IP Right Cessation
- 2002-06-18 CN CNB028123913A patent/CN1280288C/zh not_active Expired - Fee Related
- 2002-06-18 PL PL02367525A patent/PL367525A1/xx not_active Application Discontinuation
- 2002-06-18 CA CA2448798A patent/CA2448798C/en not_active Expired - Fee Related
- 2002-06-18 UA UA2004010350A patent/UA78708C2/uk unknown
- 2002-06-18 MX MXPA03011522A patent/MXPA03011522A/es active IP Right Grant
- 2002-06-18 JP JP2003507087A patent/JP4520144B2/ja not_active Expired - Fee Related
- 2002-06-18 HU HU0400233A patent/HUP0400233A3/hu unknown
- 2002-06-18 AU AU2002316533A patent/AU2002316533B2/en not_active Ceased
- 2002-06-18 EP EP02746846A patent/EP1397356B1/en not_active Expired - Lifetime
- 2002-06-18 NZ NZ530312A patent/NZ530312A/en unknown
- 2002-06-18 EA EA200400054A patent/EA009696B1/ru not_active IP Right Cessation
- 2002-06-18 DE DE60232328T patent/DE60232328D1/de not_active Expired - Lifetime
- 2002-06-18 AT AT02746846T patent/ATE431346T1/de not_active IP Right Cessation
- 2002-06-18 IL IL15944902A patent/IL159449A0/xx unknown
- 2002-06-20 AR ARP020102315A patent/AR036101A1/es unknown
-
2003
- 2003-12-17 EC EC2003004904A patent/ECSP034904A/es unknown
- 2003-12-17 NO NO20035635A patent/NO326316B1/no unknown
- 2003-12-19 CO CO03111217A patent/CO5540286A2/es not_active Application Discontinuation
-
2004
- 2004-01-19 ZA ZA200400380A patent/ZA200400380B/en unknown
- 2004-07-20 US US10/894,618 patent/US6939886B2/en not_active Expired - Fee Related
-
2005
- 2005-06-22 US US11/158,881 patent/US7351730B2/en not_active Expired - Fee Related
-
2008
- 2008-02-05 US US12/026,272 patent/US7629377B2/en not_active Expired - Fee Related
- 2008-10-20 NO NO20084390A patent/NO20084390L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP034904A (es) | Derivados de índole naftil sustituido como inhibidores del activador plasminogen del inhibidor tipo-1 (pai-1) | |
NO20014485L (no) | Nye forbindelser og sammensetninger som proteaseinhibitorer | |
EA200400073A1 (ru) | Пирролопиримидины как ингибиторы протеинкиназы | |
EP1248612A4 (en) | NEW SUBSTANCES AND COMPOUNDS AS PROTEASE INHIBITORS | |
BR9813360A (pt) | Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz (mmp) | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
ATE159950T1 (de) | N-alkyl-2-substituierte atp-analoge | |
NO20060192L (no) | Terapeutiske midler anvendelige for behandling av smerte | |
ES2170252T3 (es) | Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde. | |
AR035812A1 (es) | Compuestos de acrilamida farmaceuticamente efectivos como inhibidores de la enoil-acp reductasa-fabi-; composiciones formuladas con dichos compuestos, metodo para inhibir dicha reductasa , respectivamente, para tratar infecciones bacterianas utilizando dichos compuestos y uso de los compuestos menci | |
ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
AP2003002929A0 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister | |
PA8561501A1 (es) | Lactamas como antagonistas de taquiquininas | |
AR013462A1 (es) | Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos | |
HUP0203118A2 (hu) | Béta-diszubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
SE0102058D0 (sv) | New Salts II | |
DE60034580D1 (de) | Peptid zur behandlung von nervenerkrankungen | |
EA200301315A1 (ru) | Новые соединения и композиции в качестве ингибиторов катепсиса |